



HPTN

HIV Prevention
Trials Network

Community acceptability of injections

Experience from HPTN 077

**Steve Mphonda
UNC Project
Lilongwe
Malawi
16th June 2016**

Introduction

HPTN 077

- Multi-site, double-blind, two-arm, randomized, placebo-controlled trial which will determine whether 744LA is safe and tolerable in low-risk HIV-uninfected men and women
- Eligible participants will begin an oral lead-in phase in which they will be randomized to receive daily oral 744 or matching placebo for 4 weeks, followed by a one week washout period, to assess safety prior to receiving 744LA.

Continue

- Current antiretroviral therapy (ART) require life long adherence to daily pill taking
- Currently, no long-acting ART are approved although 744 LA is being studied.
- New preventive modalities are need

Community engagement activities

- Critical for study acceptance and participation in the study
- Sites made specific community engagement plans that suits them and for this study

CAB members debriefing

- Were very excited to see the emergence of this study.
- The prospect of an injectable ART was exciting and was long over due.
- They were of the opinion that the communities would accept and be willing to participate.
- They said that most of the people in the community would understand the need for and injectable ART.

Health facility debriefing

- Six health facilities in the catchment area were debriefed targeting all health workers at the facilities.
- Members were very interested in the study and were eager to see how clients would react to both the study and the product once enrolled.
- They were of the opinion that it was high time an injectable ART was introduced and this was a good initiative.


Potential participants

- Potential participants were of the view that this is a good study, but it should have rather enrolled HIV+ than HIV-
- The general view of the injectable ART was that this was acceptable and they would be willing participate.
- HIV+ individuals were more interested to participate in the study but due to the eligibility criteria were not allowed to.

Chief's debriefing

- The community team set out to engage and debrief 100 local leaders.

CHIEF DEBRIEFING.



Reasons for not accepting the study

- Cannot be removed once given → prolonged side effects
- Pain
- This will increase promiscuity
- Should be given to HIV +

Summary

The community has accepted the injectable ARVs and are looking forward to participating in the study.

ACKNOWLEDGEMENTS

The HIV Prevention Trials Network is sponsored by the National Institute of Allergy and Infectious Diseases, the National Institute of Mental Health, and the National Institute on Drug Abuse, all components of the U.S. National Institutes of Health.

HPTN team and all stakeholders